Sarilumab联合传统合成DMARDs治疗TNF抑制剂应答不足的活动性RA
该研究评估sarilumab联合传统合成DMARDs用于活动性中重度RA且对抗TNF治疗应答不足或不耐受的患者疗效与安全性。结果显示sarilumab 150mg与200mg每2周一次均显著提高第24周ACR20应答率并改善第12周HAQ DI,安全性与IL-6受体阻断及sarilumab已知安全性一致。
要点
- sarilumab 150mg和200mg每2周一次联合csDMARDs可显著提高抗TNF失败RA患者的ACR20应答
- 两剂量组第12周HAQ DI改善均显著优于安慰剂
- 安全性总体与IL-6受体阻断及sarilumab已知特征一致
核心结论
- sarilumab 150mg和200mg每2周一次联合传统合成DMARDs可改善抗TNF药物应答不足或不耐受RA患者的疾病活动与躯体功能。
- 安全性数据与IL-6受体阻断及sarilumab已知安全性特征一致。
研究设计与样本
- 随机对照研究,患者随机接受sarilumab 150mg、sarilumab 200mg或安慰剂每2周一次共24周,背景为传统合成DMARDs。
- 共同主要终点为第24周ACR20应答比例和第12周HAQ DI较基线变化,每个sarilumab剂量分别与安慰剂比较,未评估两剂量间差异。
主要发现
- 第24周ACR20应答率:sarilumab 150mg为55.8%、sarilumab 200mg为60.9%、安慰剂为33.7%(P < 0.0001)。
- 第12周HAQ DI较基线最小二乘均值变化:sarilumab 150mg为-0.46(P = 0.0007),sarilumab 200mg为-0.47(P = 0.0004),安慰剂为-0.26。
- 感染为最常见治疗中出现的不良事件;严重感染发生率在安慰剂、sarilumab 150mg、sarilumab 200mg组分别为1.1%、0.6%、1.1%。
- 实验室异常包括两个sarilumab组较安慰剂出现中性粒细胞绝对计数下降和转氨酶升高;本研究中中性粒细胞绝对计数下降与感染或严重感染发生率增加无关。
关键数值与推荐
- 第24周ACR20应答率分别为sarilumab 150mg 55.8%、sarilumab 200mg 60.9%、安慰剂33.7%(P < 0.0001)。
- 第12周HAQ DI最小二乘均值变化分别为sarilumab 150mg -0.46(P = 0.0007)、sarilumab 200mg -0.47(P = 0.0004)、安慰剂-0.26。
- 严重感染发生率分别为安慰剂1.1%、sarilumab 150mg 0.6%、sarilumab 200mg 1.1%。
临床怎么用
- 对传统合成DMARDs背景治疗下抗TNF药物应答不足或不耐受的活动性中重度RA患者,可考虑加用sarilumab 150mg或200mg每2周一次。
- 用药期间应关注感染及中性粒细胞绝对计数下降、转氨酶升高等实验室异常。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapy. METHODS: Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co-primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed. RESULTS: The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P < 0.0001). The mean change from baseline in the HAQ DI score at week 12 was significantly greater for sarilumab (least squares mean change: for 150 mg, -0.46 [P = 0.0007]; for 200 mg, -0.47 [P = 0.0004]) versus placebo (-0.26). Infections were the most frequently reported treatment-emergent adverse events. Serious infections occurred in 1.1%, 0.6%, and 1.1% of patients receiving placebo, sarilumab 150 mg, and sarilumab 200 mg, respectively. Laboratory abnormalities included decreased absolute neutrophil count and increased transaminase levels in both sarilumab groups compared with placebo. In this study, reductions in the absolute neutrophil count were not associated with an increased incidence of infections or serious infections. CONCLUSION: Sarilumab 150 mg and sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs improved the signs and symptoms of RA and physical function in patients with an inadequate response or intolerance to anti-TNF agents. Safety data were consistent with interleukin-6 receptor blockade and the known safety profile of sarilumab.
引用
- Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2017. PMID: 27860410. doi:10.1002/art.39944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。